Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Rare Disease Treatment Market

Rare Disease Treatment Market Share

Report ID: GMI3873
Published Date: May 2024
Report Format: PDF

Download Free Sample

Rare Disease Treatment Market Share

The competitive landscape of the market is characterized by the presence of established pharmaceutical companies that manufacture and conduct intense R&D activities to provide rare disease treatment vying for market share. Key players are engaging in strategic initiatives such as collaboration, product launch, investment, and partnerships to strengthen their product portfolio. The companies are actively adopting a multi-pronged approaches to address the rising demand for rare disease treatment.

Rare Disease Treatment Market Companies

Prominent players operating in the rare disease treatment industry are as mentioned below:

AbbVie Inc.
Alexion Pharmaceuticals, Inc.
Amgen Inc
AstraZeneca PLC
Baxter International
Bayer AG
Biogen
Bristol-Myers Squibb
Eli Lilly and Company
F. Hoffmann La Roche Ltd
GSK plc
Johnson & Johnson
Merck & Co. Inc.
Novartis AG
Novo Nordisk
Pfizer, Inc.
Pharmacyclics LLC
Sanofi SA
Seagen Inc.
Takeda Pharmaceutical Company Limited.
Vertex Pharmaceutical, Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Rare disease treatment market size was USD 205.3 billion in 2023 and is expected to register over 9% CAGR from 2024-2032 owing to the increasing prevalence of cancer and other rare diseases across the globe.

Rare disease treatment industry from the biologics segment reached USD 166.9 billion in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to its several benefits, such as, high specificity, low toxicity, extreme sensitivity to physical conditions, etc.

North America rare disease treatment industry held 48.8% share in 2023 and is expected to register a commendable CAGR from 2024-2032 due to an increase in the number of rare diseases, and rising awareness regarding the benefits of precision medicine in the region.

Bayer AG, Biogen, GSK plc, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Novo Nordisk, Pfizer, Inc., Pharmacyclics LLC, Sanofi SA, Seagen Inc., Takeda Pharmaceutical Company Limited., and Vertex Pharmaceutical, Inc., are some of the major rare disease treatment companies worldwide.